AzTrials
AzTrials

ARTHiCARTNCT03719703

Health in Childhood Following Assisted Reproductive Technology

An observational study of ART and IVF, run by Anja Bisgaard Pinborg at 1 site in Denmark.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this trial is to investigate the metabolic and cardiovascular health in children aged 6-8 years born after in-vitro fertilization with frozen embryo transfer Read more about this study

Who is it for?
Ages 6 to 8 yearsHealthy volunteers can take part
Conditions the study is for
ART, IVF, Cardiovascular Risk Factor
How many people
606 participants
Where
1 siteDenmark
Study dates
5 Jan 2019to 1 Sep 2021
How long will I take part?
5 Years
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 8 years
  • All sexes
  • Healthy volunteers accepted
  • Child

Study population: The study population will be recruited from the Capital Region of Denmark.

Who may be able to join

  • Children born after frozen embryo transfer, fresh embryo transfer and natural conception
  • Age 6 - 8 years

Who cannot join

  • The mother of childrens with diabetes mellitus type I or II
  • Gestational diabetes

Trial locations and contacts

1 site in 1 country.

Denmark1 site
  • Fertilitetsklinikken 4071

    Copenhagen

Other trials in Denmark

About this study

Official title: Cardiovascular and Metabolic Profiles in Pre-pubertal Singletons Aged 6-8 Years of Age Conceived After Frozen Embryo Transfer Compared to Singletons Conceived After Fresh Embryo Transfer and After Natural Conception

The purpose of this trial is to investigate the metabolic and cardiovascular health in children aged 6-8 years born after in-vitro fertilization with frozen embryo transfer

Read the detailed description

The investigators aim to conduct a clinical follow-up study of three groups of children: Exposed children conceived by ART(assisted reproductive technology) after frozen embryo transfer (FET) and two unexposed control groups; (1) Children conceived by ART after fresh embryo transfer and (2) Naturally conceived children. All children will be identified via their mother's CPR number in the in-vitro fertilization (IVF) and medical birth registry. Only singletons 6-8 years of age (birth year 2009-2011) born in hospitals in the Capital Region will be included. Access to maternal postal addresses will be retrieved through the CPR registry. The investigators will contact the mothers by an invitation letter by post including the patient information and the information for the child. The invitation letter and patient information will be similar for study and control groups. The mothers can reply via sms, email or telephone. If they do not reply within 2 weeks, the investigators will send them one postal reminder. In case they respond, the investigators will schedule the visit. The investigators will start contacting and examining the oldest children. Children of mothers with preexisting diabetes (type 1 or type 2) or gestational diabetes will be excluded the study.

Subjects:

  • Singletons conceived by ART after FET (N=200)
  • Singletons conceived by ART after fresh embryo transfer (N=200). (N~1000 mothers will be contacted, 40% of eligible ART subjects are expected to participate).
  • Singletons born after natural conception (N=200). A random sample of naturally conceived children matched with FET children on month and year of birth and child sex (N~ 670, 30% of eligible subjects are expected to participate).

Clinical examinations:

The clinical examinations of the children will be carried out in the Clinic of Growth and Reproduction and Clinic of Cardiology at Rigshospitalet. The investigators aim that each child attends all examinations at the same day and the full examination will last no longer than 30-40 minutes. The participants meet fasting in the morning and a fasting blood sample will be collected. Local anesthetic cream will be sent to all participants prior to the examination. The fasting blood sample will be analyzed for: Glucose profile: glucose, insulin, c-peptid (calculation of HOMA-IR), HbA1c - Lipid profile: Total cholesterol, LDL, HDL, Triglycerides - Growth factors: IGF-I and IGFBP-3 - Androgen status and Anti Müllerian Hormone (AMH) - Lipids and cytokines (CRP, IL-6, adiponectin, leptin, inkretin) - Biobank sampling The clinical examination includes determination of: Height, weight, waist and hip circumference - Skinfold measurements (Harpenden Skinfold Caliper) - Pubertal staging (Tanner) - Blood pressure (systolic, diastolic) measured by FINA press device (valid continuous measurements)

In a subset of children n=50 in each group (in total 150 children) the investigators will perform a cardiovascular magnetic resonance imaging (CMR):

  • Magnetic resonance imaging (MRI) determined diastolic and systolic function of cardiac chambers and large vessels of the thorax, and measurement of epi- and pericardial fat tissue

Scientific objective I:

Determination of risk of obesity and metabolic disease in children conceived by ART with FET compared to children conceived after fresh embryo transfer and after natural conception. The primary outcome is overweight and obesity as determined by BMI (SDS for age). Secondary outcome measures are fat percentage measured by skinfolds and abdominal circumference, visceral fat (MRI) and calculation of insulin sensitivity (HOMA-IR) as a risk marker of altered metabolism and epigenetic changes of metabolic pathways, growth factors and andrenal androgens.

Scientific objective II:

Determination of markers of cardiovascular risk in children whose mothers conceived by FET compared to children conceived after ART fresh embryo transfer and after natural conception. Cardio-vascular outcome measures will be left ventricular (LV) and right ventricular (RV) myocardial mass and function, pulmonary artery and aortic distensibility and estimation of epi- and pericardial fat tissue.

Statistics:

Continuous outcome measures will be compared between the three groups using multiple linear regression with adjustment for potential confounding factors and child sex. In case of pronounced skewness, logarithmic transformation will be applied prior to analysis. Binary outcomes will be compared between the three groups using multiple logistic regression with adjustment for potential confounders and child sex. Additional multiple regression analysis with further inclusion of potential mediators will be performed to identify maternal/fetal and neonatal predictive factors for the different outcomes. Background characteristics will be compared between the three groups using one-way ANOVA for normally distributed data, the Kruskal-Wallis test for non-normally distributed continuous data, and the chi-square test for categorical data. P-values from secondary and explorative data analyses will be adjusted for multiple testing by controlling the false discovery rate to 5% as recommended for health science studies.

Sample size calculation:

Scientific objective I:

BMI was chosen as our primary endpoint and the investigators calculated the age specific BMI based on the Tinggard cohort.30 Childhood and adolescent BMI show dose-dependent association with adult mortality, with an increase in 1 SD in BMI z-score at age 8 years showing a HR of 1.13 of a fatal cardiovascular event in adulthood. The minimal clinically important difference in BMI was set as 0.3 SD scores, corresponding to an increased HR of 3.4%. Thus, with equal size groups, a significance level of 5% and power 90% there should be 191 children in each group to detect the minimal relevant difference. With 200 children in each group the investigators anticipate that the sample size will be sufficiently large to compensate for degrees of freedom lost due to adjustment for confounding factors (as in particular the inclusion of the confounders will imply a reduction of the residual variance).

Scientific objective II:

Power calculation for the right heart study:

The previously found differences in hypoxic vasoconstriction were not evidenced by an increased systolic pressure of the right ventricle at rest perhaps because the right ventricle is thin-walled and accommodating. Considering that pre-pubertal children may vary slightly in absolute heart size from adults, the investigators use the ratio of RVEDV/LVEDV for the power calculation. Thus, while normally close to 1.0, with poor run-off for the RV into the pulmonary circulation the investigators expect an increase in the RVEDV/LVEDV ratio >1.2 corresponding to a >20% increase in RVEDV in comparison with the LVEDV (that now acts like an "internal comparator"). With a conservative estimate for the common SD for the difference of 0.35, with an alpha of 0.05 and power (1-beta) of 0.80 the investigators will be able to detect a difference between groups of RVEDV/LVEDV from 1.0 to 1.20 with 36 children in each group (double-sided). The investigators aim for 50 children in each group to allow for drop-outs including non-analysable scans.

Power calculation for the left heart study:

With impaired flow-mediated vasodilatation in IVF children, the investigators expect arterial distensibility to decrease. With age (and disease) arterial distensibility decreases. To be clinically meaningful the investigators have based our power calculations on children aged 10 years born after IVF having stiff aortas comparable to "being 5-years older". With a conservative estimate for the common SD for the difference of 1.5 mm2/mmHg, with an alpha of 0.05 and a beta of 0.80 the investigators will be able to detect a difference between groups of aortic distensibility from 8.9 to 8.0 mm2/mmHg (based on data from 10 and 15-year old boys, respectively with 44 children in each group (double-sided). The investigators aim for 50 children in each group to allow for drop-outs including non-analysable scans.

Power calculation for the epicardial and pericardial fat tissue study:

Recent MRI and echocardiographic studies have demonstrated that children with obesity and metabolic syndrome may have more than two-fold as much epicardial and pericardial fat tissue than lean children, and that this is related to cardiac remodelling including left ventricular hypertrophy and impaired left ventricle longitudinal strain. In this study, anticipating smaller changes, we expect a >20% higher epicardial as well as pericardial fat tissue to be present in children born after IVF. With a conservative estimate for the common SD for the difference of 30% of the mean, with an alpha of 0.05 and a beta of 0.80 the investigators will be able to detect a difference between groups of aortic distensibility of 20% with 36 children in each group (double-sided). The investigators aim for 50 children in each group to allow for drop-outs including non-analysable scans.

Approvals:

The project has been approved by the Scientific Ethics Committee in the Capital Region, Denmark and by the Danish Data Protection Agency (Datatilsynet). Data from patient files will not be used in the study. The study will be conducted in accordance with the Helsinki Declaration and according to the Danish law on person identifiable data.

Keywords
Frozen embryo transfer; cardiovascular; metabolic; IVF
Medical subject headings
Hypertension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT03719703
Study groupRoleWhat they receive
Case 1Children conceived by frozen embryo transfer
Case 2Children conceived by fresh embryo transfer
ControlNaturally conceived children

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. BMI

    We want to investigate BMI status among FET children as hight BMI is known to be a risk factor for cardiovascular disease

    Measured: At admission

  2. Cardiovascular risk profiling with cardiac MRI

    Determination of markers of cardiovascular risk by cardiac MRI of left and right site of the heart, distensibility of pulmonary artery and aorta and the amount of epi- and pericardial fat in children conceived by FET compared to natural conceived children.

    Measured: At admission

Secondary outcomes (4)
  1. HOMA-IR

    Insulin sensitivy

    Measured: At admission

  2. DXA scan

    Total fat, muscle and bone mass

    Measured: At admission

  3. Epigenetics

    Analysis of DNA-methylation, acetylation and histone modifications

    Measured: After admission

  4. Blood pressure

    Continues blood pressure measurement

    Measured: at admission

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Oct 2018
  2. Study start5 Jan 2019
  3. Primary completion1 Sep 2021
  4. Study completion1 Sep 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
606 participants (actual)
Target duration
5 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT03719703
Sponsor's protocol ID
H-18000122
Acronym
HiCART
Status last verified
Mar 2023
First submitted
23 Oct 2018
Last updated
30 Mar 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Gronlund EW, Kjaer ASL, Asserhoj LL, Mizrak I, Clausen TD, Madsen PL, Pinborg A, Jensen RB. Bone mineralization in children aged 7-10 years born after ART with frozen and fresh embryo transfer. Hum Reprod Open. 2025 Sep 11;2025(4):hoaf055. doi: 10.1093/hropen/hoaf055. eCollection 2025.

    PubMed 40989217
  • Olsen AR, Asserhoj LL, Pinborg A, Clausen TD, Greisen G, Jensen RB, Main KM, Vejlstrup NG, Madsen PL, Mizrak I. Visceral and subcutaneous adipose tissue in children born after ART with frozen and fresh embryo transfers. Hum Reprod Open. 2025 Mar 17;2025(2):hoaf014. doi: 10.1093/hropen/hoaf014. eCollection 2025.

    PubMed 40196045
  • Asserhoj LL, Mizrak I, Lebech Kjaer AS, Clausen TD, Hoffmann ER, Greisen G, Main KM, Madsen PL, Pinborg A, Jensen RB. Blood pressure and lipid profiles in children born after ART with frozen embryo transfer. Hum Reprod Open. 2024 Mar 20;2024(2):hoae016. doi: 10.1093/hropen/hoae016. eCollection 2024.

    PubMed 38600915
  • Asserhoj LL, Mizrak I, Heldarskard GF, Clausen TD, Hoffmann ER, Greisen G, Main KM, Madsen PL, Jensen RB, Pinborg A. Childhood BMI after ART with frozen embryo transfer. Hum Reprod. 2023 Aug 1;38(8):1578-1589. doi: 10.1093/humrep/dead127.

    PubMed 37349895
  • Mizrak I, Asserhoj LL, Lund MAV, Kielstrup LR, Greisen G, Clausen TD, Main KM, Jensen RB, Vejlstrup NG, Madsen PL, Pinborg A. Cardiovascular function in 8- to 9-year-old singletons born after ART with frozen and fresh embryo transfer. Hum Reprod. 2022 Mar 1;37(3):600-611. doi: 10.1093/humrep/deab284.

    PubMed 35015837

Questions about this trial

What is this clinical trial studying?

An observational study of ART and IVF, run by Anja Bisgaard Pinborg at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

BMI (time frame: At admission). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03719703, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Mar 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in